Oncology Drug Report - Kadcyla - ado-trastuzumab emtansine - 2013-2015 Analysis; 2016-2021 Expectations

  • ID: 4018717
  • Report
  • Region: Global
  • 54 Pages
  • Cancer Research Analytics
1 of 5
The Drug Has Seen a Successful Start and Sales Are Likely to Grow in the Near Future

FEATURED COMPANIES

  • AstraZeneca
  • Eisai
  • GlaxoSmithKline
  • Novartis
  • Puma Biotech
  • Roche
  • MORE

“Kadcyla (ado-trastuzumab emtansine): Armed antibody” is a comprehensive report on the first USFDA approved drug with antibody–drug conjugate for HER2-positive metastatic breast cancer treatment.

Kadcyla falls in the monoclonal antibody, HER 2-targeted antibody-drug conjugate, class of drugs belonging to the targeted therapy. It is indicated for the treatment of HER2-positive metastatic breast cancer.

The report provides basic information about the drug, covering all details such as brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events around the drug, news about Kadcyla, information on clinical studies of ongoing trials, number of clinical trials (by year and by phase), clinical study data about Kadcyla and other competing drugs and so on.

The report gives an analysis of the historical annual sales (from 2013 to Q3-2016), historical quarterly sales (Q1-2013 to Q3-2016), cumulative sales until date, Q3-2016 update and sales expectations (from 2016-2021). The analysis broadly indicates that the drug has seen a successful start and sales are likely to grow in the near future.

Details of the sales analysis section

Historical annual sales analysis: Historical annual sales have been analysed in USD and CHF terms with the help of graphical representation of sales over 2013-2015. The report has all the data in tabular format as well. We have highlighted key reasons for the sales trend in all the geographies listed.

Historical quarterly sales analysis: Additionally, we have sales analysis on quarterly basis for the last 15 quarters from Q1-2013 to Q3-2016. The quarterly data is also in graphical as well as tabular format.

Expected sales analysis: The report has our expectations for sales of Kadcyla over 2016-2021.

We have highlighted key reasons for our expectations. All the historical as well as expected sales analysis is based on:

  • Total global sales
  • US sales
  • International sales
    • Europe sales
    • Japan sales
    • RoW sales

Other important details

Key event tracker: The report highlights key events that have taken place for Kadcyla from 2013 to 2015. It gives additional information about which key events have driven sales for Kadcyla over this period.

Competitive drugs: We have provided information on competitor drugs in the market that are used in the treatment of the same indications as Kadcyla with their details including brand name, API, company, class of drug, therapy class and treatment preference.

Pipeline drugs: We have provided information on pipeline drugs in the market that will be used in the treatment of the same indications as Kadcyla with their details including drug name, API, company, class of drug, phase, therapy class and treatment preference.

Clinical trials numbers: The report provides numbers of clinical trials that have started for Kadcyla in 2016, 2015 and 2014 and for different phases: phase II, phase II/III and phase III. It gives insights into whether the company is still spending money for taking the drug even further for other indications or in combination therapies.

Clinical studies: Efficacy results of Kadcyla and its competing drugs have been provided.

News: We have listed news related to Kadcyla that would impact the drug’s performance.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Eisai
  • GlaxoSmithKline
  • Novartis
  • Puma Biotech
  • Roche
  • MORE

1. Basic Information
1.1 Brand name/multiple brand names (US, Europe, Japan, RoW)
1.2 Research code
1.3 API
1.4 Molecular weight
1.5 Molecular structure
1.6 Immuno-oncology status
1.7 Broader indications
1.8 Therapy class
1.9 Class of drug
1.10 Companies involved in marketing (US, Europe, Japan, RoW)
1.11 Innovation-related information
1.12 First approval dates (US, Europe, Japan)
1.13 Patent expiry dates (US and Europe)
1.14 Molecule type
1.15 Dosage form/strength
1.16 Route of administration
1.17 Global sales-2015/2016E (USD, bn)
1.18 Mechanism of action
1.19 Pharmacodynamic properties
1.20 Pharmacokinetic properties
1.21 Co-promotion agreement
1.21 Royalty-related information

2. Approval timeline infographic (2012-2015)
3. Regulatory approval details (US, Europe, Japan and RoW)
3.1 Approval table of three major geographies
3.2 Drug approvals in some of the RoW countries

4. Historical annual sales analysis (2013-2015, 2016E)
4.1 Total sales (USD)
4.2 Total sales (CHF)
4.3 Sales mix - US/international
4.4 US sales (USD)
4.5 US sales (CHF)
4.6 International sales (USD)
4.7 International sales (CHF)
4.8 Europe sales (USD)
4.9 Europe sales (CHF)
4.10 Japan sales (USD)
4.11 Japan sales (CHF)
4.12 RoW sales (USD)
4.13 RoW sales (CHF)
4.14 Historical annual sales table (USD)
4.15 Historical annual sales table (CHF)

5. Historical quarterly sales analysis (Q1-2013 to Q3-2016)
5.1 Total sales (USD)
5.2 Total sales (CHF)
5.3 Sales mix - US/international
5.4 US sales (USD)
5.5 US sales (CHF)
5.6 International sales (USD)
5.7 International sales (CHF)
5.8 Europe sales (USD)
5.9 Europe sales (CHF)
5.10 Japan sales (USD)
5.11 Japan sales (CHF)
5.12 RoW sales (USD)
5.13 RoW sales (CHF)
5.14 Historical annual sales table (USD)
5.15 Historical annual sales table (CHF)

6. Historical cumulative sales (2012 to Q3-2016)
6.1 Total sales (USD)
6.2 US sales (USD)
6.3 International sales (USD)
6.4 Europe sales (USD)
6.5 Japan sales (USD)
6.6 RoW sales (USD)
6.7 cumulative sales table (USD)

7. Q3-2016 update
7.1 Q3-2015 to Q3-2016 quarterly total sales (USD)
7.2 Q3-2015 to Q3-2016 quarterly US sales (USD)
7.3 Q3-2015 to Q3-2016 quarterly international sales(USD)
7.4 Q3-2015 to Q3-2016 quarterly Europe sales (USD)
7.5 Q3-2015 to Q3-2016 quarterly Japan sales (USD)
7.6 Q3-2015 to Q3-2016 quarterly RoW sales (USD)
7.4 Quarterly sales table (Q3-2015 to Q3-2016 in USD)

8. Sales expectations (2016E-2021E)
8.1 Total sales (USD)
8.2 Total sales (CHF)
8.3 Sales mix - US/international
8.4 US sales (USD)
8.5 US sales (CHF)
8.6 International sales (USD)
8.7 International sales (CHF)
8.8 Europe sales (USD)
8.9 Europe sales (CHF)
8.10 Japan sales (USD)
8.11 Japan sales (CHF)
8.12 RoW sales (USD)
8.13 RoW sales (CHF)
8.14 Expected annual sales table (USD)
8.15 Expected annual sales table (CHF)

9. Ongoing trials of Kadcyla

10.Clinical studies outcome of Kadcyla in second-line treatment of HER2-positive advanced gastric cancer
10.1 Clinical studies outcome of Kadcyla in first-line treatment of HER2-positve metastatic breast cancer

11. List of key approved drugs in breast cancer
11.1 Approved drugs in breast cancer market (other than HER2- positive)
11.2 Approved drugs in HER-2 positive breast cancer market
11.3 Table for the basis of drugs approved for HER2 - positive breast cancer
11.4 Pipeline drug in HER2-positive breast cancer market

12. Clinical studies results of neratinib ExteNET trial
12.1 Clinical studies results for competing drugs

13. Event tracker

14. Clinical trials of Kadcyla (US)
14.1 Year-wise (2014, 2015 and 2016)
14.2 Phase-wise (II, II/III, III)

15. News around Kadcyla

16. Annexure
16.1 Drug coverage list of 251 drugs

17. Methodology

18.  Disclaimer

List of Exhibits

Exhibit 1: Approval infographic
Exhibit 2: Drug approvals table across the three major geographies
Exhibit 3: Drug approvals table in RoW
Exhibit 4: Historical annual total sales in USD mn
Exhibit 5: Historical annual total sales in CHF mn
Exhibit 6: Historical annual sales mix - US/international
Exhibit 7: Historical annual US sales in USD mn
Exhibit 8: Historical annual US sales in CHF mn
Exhibit 9: Historical annual international sales in USD mn
Exhibit 10: Historical annual international sales in CHF mn
Exhibit 11: Historical annual Europe sales in USD mn
Exhibit 12: Historical annual Europe sales in CHF mn
Exhibit 13: Historical annual Japan sales in USD mn
Exhibit 14: Historical annual Japan sales in CHF mn
Exhibit 15: Historical annual RoW sales in USD mn
Exhibit 16: Historical annual RoW sales in CHF mn
Exhibit 17: Historical annual sales table in USD mn
Exhibit 18: Historical annual sales table in CHF mn
Exhibit 19: Average annual exchange rates table (USD/CHF)
Exhibit 20: Historical quarterly total sales in USD mn
Exhibit 21: Historical quaterly total sales in CHF mn
Exhibit 22: Historical quarterly sales mix - US/international
Exhibit 23: Historical quarterly US sales in USD mn
Exhibit 24: Historical quarterly US sales in CHF mn
Exhibit 25: Historical quarterly international sales in USD mn
Exhibit 26: Historical quarterly international sales in CHF mn
Exhibit 27: Historical quarterly Europe sales in USD mn
Exhibit 28: Historical quarterly Europe sales in CHF mn
Exhibit 29: Historical quarterly Japan sales in USD mn
Exhibit 30: Historical quarterly Japan sales in CHF mn
Exhibit 31: Historical quarterly RoW sales in USD mn
Exhibit 32: Historical quarterly RoW sales in CHF mn
Exhibit 33: Historical quarterly sales table in USD mn
Exhibit 34: Historical quarterly sales table in CHF mn
Exhibit 35: Historical cumulative annual total sales in USD mn
Exhibit 36: Historical cumulative annual US sales in USD mn
Exhibit 37: Historical cumulative annual international sales in USD mn
Exhibit 38: Historical cumulative annual Europe sales in USD mn
Exhibit 39: Historical cumulative annual Japan sales in USD mn
Exhibit 40: Historical cumulative annual RoW sales in USD mn
Exhibit 41: Historical cumulative annual sales table in USD mn
Exhibit 42: Q3-2015 to Q3-2016 quarterly total sales in USD mn
Exhibit 43: Q3-2015 to Q3-2016 quarterly US sales in USD mn
Exhibit 44: Q3-2015 to Q3-2016 quarterly international sales in USD mn
Exhibit 45: Q3-2015 to Q3-2016 quarterly Europe sales in USD mn
Exhibit 46: Q3-2015 to Q3-2016 quarterly Japan sales in USD mn
Exhibit 47: Q3-2015 to Q3-2016 quarterly RoW sales in USD mn
Exhibit 48: Quarterly sales table (Q3-2015 to Q3-2016 in USD)
Exhibit 49: Expected annual total sales in USD mn
Exhibit 50: Expected annual total sales in CHF mn
Exhibit 51: Expected annual sales mix - US/international
Exhibit 52: Expected annual US sales in USD mn
Exhibit 53: Expected annual US sales in CHF mn
Exhibit 54: Expected annual international sales in USD mn
Exhibit 55: Expected annual international sales in CHF mn
Exhibit 56: Expected annual Europe sales in USD mn
Exhibit 57: Expected annual Europe sales in CHF mn
Exhibit 58: Expected annual Japan sales in USD mn
Exhibit 59: Expected annual Japan sales in CHF mn
Exhibit 60: Expected annual RoW sales in USD mn
Exhibit 61: Expected annual RoW sales in CHF mn
Exhibit 62: Expected annual sales table in USD mn
Exhibit 63: Expected annual sales table in CHF mn
Exhibit 64: Clinical trials of Kadcyla
Exhibit 65:Results of GATSBY trial
Exhibit 66:Results of MARIANNE trial
Exhibit 67: Approved drugs in breast cancer market (other than HER2- positive)
Exhibit 68: Approved drugs in HER2-positive breast cancer
Exhibit 69:Basis of drugs approved in HER2-postive breast cancer
Exhibit 70: Pipeline drug in HER2-positive breast cancer market
Exhibit 71: Results of neratinib clinical trial
Exhibit 72: Efficacy results for the approval of Kadcyla
Exhibit 73: Herceptin efficacy results in first line treatment for metastatic breast cancer
Exhibit 74: Efficacy results for the approval of perjeta
Exhibit 75: Efficacy results for the approval of Perjeta in neoadjuvant treatment
Exhibit 76: Efficacy results for the approval of Tykerb
Exhibit 77: Efficacy results for the approval of Tykerb
Exhibit 78: Event tracker
Exhibit 79: Year-wise clinical trials (2016)
Exhibit 80: Year-wise clinical trials (2015)
Exhibit 81: Year-wise clinical trials (2014)
Exhibit 82: Year-wise clinical trials table (2016)
Exhibit 83: Year-wise clinical trials table (2015)
Exhibit 84: Year-wise clinical trials table (2014)
Exhibit 85: Phase-wise clinical trials (Phase-3)
Exhibit 86: Phase-wise clinical trials (Phase-2/3)
Exhibit 87: Phase-wise clinical trials (Phase-2)
Exhibit 88: Phase-wise clinical trials table (Phase-3)
Exhibit 89: Phase-wise clinical trials table (Phase-2/3)
Exhibit 90: Phase-wise clinical trials table (Phase-2)
Exhibit 91:  Key events summary

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca
  • Celgene
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline
  • Kyowa Hakko Kirin
  • Novartis
  • Pfizer
  • Puma Biotech
  • R Pharm
  • Roche
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll